Johnson & Johnson has announced a more than $1-billion investment to build a new cell-therapy manufacturing facility in Montgomery County, Pennsylvania. The announcement is part of the company’s previously announced $55-billion investment in US-based manufacturing, research and development, and technology through early 2029. 

This new facility supports the company’s plans to manufacture the vast majority of its advanced medicines in the US for US patients and will further support its pipeline and portfolio for medicines treating cancer, immune-mediated and neurological diseases. The company says the new facility will support more than 500 skilled biomanufacturing jobs when fully operational and more than 4,000 construction jobs during site development. 

The $1-billion being invested in Pennsylvania continues other US investments announced by the company. Last March (March 2025), J&J announced manufacturing, research and development, and technology investments of more than $55 billion in the US through 2029, which includes a new 500,000-square-foot biologics manufacturing facility in Wilson, North Carolina, which the company started construction of last March (March 2025). In addition, last August (August 2025), J&J announced a 10-year, $2-billion deal with the CDMO Fujifilm Biotechnologies to secure a 160,000+ square foot dedicated manufacturing facility at Fujfilm’s new, large-scale biomanufacturing facility in Holly Springs, North Carolina.  

In addition, the multi-year investment includes: (1) three new advanced manufacturing facilities and the expansion of several existing sites across the company’s Innovative Medicine and MedTech businesses; (2) investments in R&D infrastructure for developing therapeutics in areas such as oncology, neuroscience, immunology, and cardiovascular disease as well as investments in robotic surgery; and (3) increased technology investments in drug-discovery and development activities, workforce training, and business operations.  

Source: Johnson & Johnson